

29.03.2023

11:30 - 13:00	Type: Industry Satellite Symposium Title: Mirati Therapeutics, Inc. - New frontiers in the treatment of advanced NSCLC Moderation: Solange Peters, Switzerland	Auditorium 2
----------------------	--	---------------------

11:30 - 11:35 **Chair's introduction**
Solange Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

11:35 - 11:55 **Treatment landscape for advanced NSCLC: Where are we now?**
Jurgen Wolf, University Hospital of Cologne, Cologne, Germany

11:55 - 12:15 **How may we overcome resistance to CPI therapy?**
Sanjay Popat, London, United Kingdom

12:15 - 12:45 **Targeting KRASG12C: Kick-starting a KRAS revolution**
Solange Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

12:45 - 13:00 **Q&A and summary**

13:00 - 13:30	Type: Coffee break Title: Welcome reception	Exhibition and Poster area
14:30 - 16:00	Type: Educational session Title: Mesothelioma: From biology to novel treatment strategies Moderation: Paul Baas, Netherlands; Anne Tsao, United States of America	Auditorium 4

14:30 - 14:50 **Insights in biology**
Paul Baas, Amsterdam, Netherlands

14:50 - 15:10 **State of the art clinical treatment / Frontline studies**
Anne Tsao, Houston, United States of America

15:10 - 15:30 **Novel targeted agents in mesothelioma**
Dean Fennell, Leicester, United Kingdom

15:30 - 15:50 **Innovative perioperative strategies**
Isabelle Opitz, University Hospital Zürich, Zurich, Switzerland

15:50 - 16:00 **Q&A**

14:30 - 16:00	Type: Educational session Title: State of the art for small cell lung cancer: Unraveling recent data	Auditorium 2
	Moderation: Charles Rudin, United States of America; Eleni Gkika, Germany	
14:30 - 14:50	Optimal first-line therapy for extensive-stage SCLC <u>Charles Rudin</u> , Memorial Sloan Kettering Cancer Center, New York, United States of America	
14:50 - 15:10	Navigating salvage therapy for advanced SCLC <u>Andrea Ardizzoni</u> , Bologna, Italy	
15:10 - 15:30	Leveraging SCLC subtypes and other biomarkers <u>Fred Hirsch</u> , New York, United States of America	
15:30 - 15:50	Controversies and standards for radiation therapy in SCLC <u>Eleni Gkika</u> , Freiburg im Breisgau, Germany	
15:50 - 16:00	Q&A	
14:30 - 16:00	Type: Multidisciplinary Tumour Board Title: Oligometastatic disease in oncogene addicted NSCLC	Auditorium 1
	Moderation: Noemi Reguart Aransay, Spain; Salma Jabbour, United States of America	
14:30 - 14:40	Case presentation <u>Noemi Reguart Aransay</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, Spain	
14:40 - 15:00	Positioning of treatment of the primary tumour <u>Salma Jabbour</u> , New Brunswick, United States of America	
15:00 - 15:20	Positioning of local treatment for oligometastases <u>Lucyna Kepka</u> , Warsaw, Poland	
15:20 - 15:40	Positioning of systemic treatment <u>Antonio Calles Blanco</u> , Madrid, Spain	
15:40 - 16:00	Q&A	
16:00 - 16:30	Type: Coffee break Title: Coffee break	Exhibition and Poster area

16:30 - 18:00	Type: Educational session Title: Updates on molecular diagnosis Moderation: Fernando Lopez-Rios, Spain; Keith Kerr, United Kingdom	Auditorium 2
16:30 - 16:50	Maximizing outcomes from molecular diagnosis (Part1 - before the molecular lab) <u>Keith Kerr</u> , Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, United Kingdom	
16:50 - 17:10	Maximizing outcomes from molecular diagnosis (Part2 - in the molecular lab) <u>Fernando Lopez-Rios</u> , Madrid, Spain	
17:10 - 17:30	Searching for fusions beyond ALK and ROS1 <u>Teodora Radonic</u> , * VU University Medical Centre, Cancer Center Amsterdam, Amsterdam, Netherlands	
17:30 - 17:50	Applying liquid biopsy as part of an integrated genomic service <u>Maria Arcila</u> , New York, United States of America	
17:50 - 18:00	Q&A	
16:30 - 18:00	Type: Educational session Title: Lung cancer beyond tobacco: Impact of environmental and other risk factors Moderation: Laura Mezquita, Spain; Boris Duchemann, France	Auditorium 4
16:30 - 16:50	Smoking and lung cancer <u>Boris Duchemann</u> , Bobigny, France	
16:50 - 17:10	Radon and other risk factors in lung cancer <u>Laura Mezquita</u> , Barcelona, Spain	
17:10 - 17:30	Air pollution and lung cancer <u>Christine Berg</u> , Bethesda, United States of America	
17:30 - 17:50	Lung cancer prevention: Patients/advocates perspective <u>Anne-Marie Baird</u> , Dublin, Ireland	
17:50 - 18:00	Q&A	

16:30 - 18:00	Type: Proffered Paper session Title: Proffered Paper 1 Moderation: Daniel Shao Weng Tan, Singapore; Heather Wakelee, United States of America	Auditorium 1
16:30 - 16:42	10 - Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial <u>Jordi Remon Masip</u> , Villejuif, France	
16:42 - 16:54	20 - Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): Analysis of Adverse Events (AEs) <u>Saumil Gandhi</u> , Houston, United States of America	
16:54 - 17:05	Invited Discussant 10 and 20 <u>Daniel Shao Weng Tan</u> , NCCS - National Cancer Centre Singapore, Singapore, Singapore	
17:05 - 17:15	Q&A	
17:15 - 17:27	30 - Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC <u>Pilar Garrido Lopez</u> , Hospital Universitario Ramon y Cajal, Madrid, Spain	
17:27 - 17:39	40 - Patient-reported outcomes from the CodeBreakK 200 phase 3 trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC <u>David Waterhouse</u> , Boston, United States of America	
17:39 - 17:50	Invited Discussant 30 and 40 <u>Jarushka Naidoo</u> , Beaumont Hospital, Dublin, Ireland	
17:50 - 18:00	Q&A	

18:15 - 19:45	Type: Industry Satellite Symposium Title: Eisai, Inc - How the new treatment paradigm of advanced early-stage NSCLC impacts later lines Moderation: Solange Peters, Switzerland	Auditorium 2
18:15 - 18:20	Welcome and introduction <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
18:20 - 18:40	Key considerations for the treatment of patients pre-treated with checkpoint inhibitors and chemotherapy <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
18:40 - 19:00	Tumour microenvironment manipulations to improve patients outcomes: A translational review <u>Fabrice Barlesi</u> , Villejuif, France	
19:00 - 19:20	Debate on chemotherapy use in high PD-L1 expressors: The pros and cons <u>Natasha Leighl</u> , Princess Margaret Cancer Centre, Toronto, Canada	
19:20 - 19:40	Expert panel discussion	
19:40 - 19:45	Conclusion <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	

18:15 - 19:45	Type: Industry Satellite Symposium Title: Pfizer Oncology - Raising the bar for patients with <i>ALK</i>+ NSCLC throughout their treatment journey Moderation: Geoffrey Liu, Canada	Auditorium 4
18:15 - 18:20	Welcome and introduction <u>Geoffrey Liu</u> , Princess Margaret Cancer Center, Toronto, Canada	
18:20 - 19:30	Follow a patient on their <i>ALK</i>+ NSCLC treatment journey by joining us for an interactive patient case study with voting and panel discussion around the following topics: 1L treatment selection for <i>ALK</i>+ NSCLC; <i>ALK</i> TKI treatment initiation; response to <i>ALK</i> TKI therapy; therapy management, and progression on 1L treatment <u>Geoffrey Liu</u> , Princess Margaret Cancer Center, Toronto, Canada	
19:30 - 19:40	Q&A and panel discussion	
19:40 - 19:45	Meeting close <u>Geoffrey Liu</u> , Princess Margaret Cancer Center, Toronto, Canada	

30.03.2023

08:00 - 09:00 **Type: Multidisciplinary Interactive session** **Auditorium**
Title: Place of radiotherapy in advanced SCLC treated with IO: Brain **2**
and thorax
Moderation: Fiona McDonald, United Kingdom; Enriqueta Felip, Spain

08:00 - 08:15 **Case presentation**
Fiona Mcdonald, London, United Kingdom

08:15 - 08:30 **What is the role of brain radiotherapy?**
Corinne Faivre-Finn, Manchester, United Kingdom

08:30 - 08:45 **What is the role of thoracic radiotherapy?**
Ben Slotman, Amsterdam, Netherlands

08:45 - 09:00 **Discussion**

08:00 - 09:00 **Type: Controversy session** **Auditorium**
Title: Is neoadjuvant chemo-immunotherapy superior to adjuvant **4**
immunotherapy?
Moderation: Lizza Hendriks, Netherlands

08:00 - 08:10 **Introduction and first vote**
Lizza Hendriks, Maastricht University Medical Center (MUMC), Maastricht, Netherlands

08:10 - 08:30 **Yes**
Egbert Smit, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

08:30 - 08:50 **No**
Heather Wakelee, Stanford, United States of America

08:50 - 09:00 **Second vote and conclusions**
Lizza Hendriks, Maastricht University Medical Center (MUMC), Maastricht, Netherlands

09:15 - 10:15	Type: Controversy session Title: Stereotactic RT vs surgery in early stage NCSLC Moderation: Corinne Faivre-Finn, United Kingdom	Auditorium 2
09:15 - 09:25	Introduction and first vote <u>Corinne Faivre-Finn</u> , Manchester, United Kingdom	
09:25 - 09:45	Yes <u>Umberto Ricardi</u> , Torino, Italy	
09:45 - 10:05	No <u>Paul Van Schil</u> , Edegem, Belgium	
10:05 - 10:15	Second vote and conclusions <u>Corinne Faivre-Finn</u> , Manchester, United Kingdom	

09:15 - 10:45	Type: ESMO Colloquium Title: ESMO Colloquium supported by Eli Lilly & Company - Precision oncology beyond EGFR/ALK for NSCLC in 2023: Test, target, manage Moderation: Solange Peters, Switzerland; Benjamin Besse, France	Auditorium 4
09:15 - 09:20	Introduction: Summary data on the ESMO Survey on Biomolecular Technology Availability <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
09:20 - 09:35	Current indications of precision therapeutics in advanced oncogene-addicted NSCLC beyond EGFR and ALK: Efficacy, safety, value <u>Benjamin Besse</u> , Institut Gustave Roussy, Villejuif, France	
09:35 - 09:50	The quest for optimal integration of biomarker testing by tissue NGS in the care pathway: Analytics, availability and reporting of actionable vs non-actionable aberrations <u>Javier Hernandez-Losa</u> , Barcelona, Spain	
09:50 - 10:00	Q&A	
10:00 - 10:15	The quest for optimal positioning of liquid biopsies in the workup of patients with NSCLC: When, for what and how often <u>Umberto Malapelle</u> , Napoli, Italy	
10:15 - 10:30	Highlighting the value of Molecular Tumour Boards: Presentation of two patient cases with oncogene-addicted NSCLC, summary of clinical evidence and insights in molecular profiling/interpretation <u>Simon Ekman</u> , Solna, Sweden	
10:30 - 10:40	Q&A and discussion	
10:40 - 10:45	Concluding remarks <u>Benjamin Besse</u> , Institut Gustave Roussy, Villejuif, France	

09:15 - 10:45	Type: Educational session Title: Resistance after IO and targeted therapies: Patterns of emergence and management Moderation: Zofia Piotrowska, United States of America; Suresh Senan, Netherlands	Auditorium 1
09:15 - 09:35	Managing acquired resistance to immunotherapy in NSCLC: Resistance mechanisms and treatment strategies <u>Maurice Perol</u> , Lyon, France	
09:35 - 09:55	Managing acquired resistance to targeted therapy in NSCLC: Resistance mechanisms and treatment strategies <u>Zofia Piotrowska</u> , Boston, United States of America	
09:55 - 10:15	Is there a role for repeat biopsies when patients progress on targeted therapy? On Immunotherapy? <u>Valsamo Anagnostou</u> , Baltimore, United States of America	
10:15 - 10:35	Optimal use of local therapy in patients with resistance to targeted therapies or immunotherapy <u>Suresh Senan</u> , Amsterdam, Netherlands	
10:35 - 10:45	Q&A	
10:45 - 11:15	Type: Coffee break Title: Coffee break	Exhibition and Poster area
11:15 - 12:45	Type: Multidisciplinary Tumour Board Title: Stage III thymoma Moderation: Nicolas Girard, France; Sanjay Popat, United Kingdom	Auditorium 4
11:15 - 11:35	Case presentation <u>Giulia Galli</u> , Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy	
11:35 - 11:55	When do we switch local to systemic and systemic to local treatment? <u>Hidehito Horinouchi</u> , Chuo-ku, Japan	
11:55 - 12:15	When to call the radiation oncologist? <u>Andreas Rimner</u> , New York, United States of America	
12:15 - 12:35	How to optimize the patient pathway? <u>Sanjay Popat</u> , London, United Kingdom	
12:35 - 12:45	Q&A	

11:15 - 12:45	Type: Educational session Title: Genomic alterations beyond EGFR and ALK Moderation: Antonio Passaro, Italy; Lyudmila Bazhenova, United States of America	Auditorium 2
11:15 - 11:35	Oncogenic fusions: Targeting ROS1, RET and NTRK <u>Misako Nagasaka</u> , Orange, United States of America	
11:35 - 11:55	New advances in BRAF and MET Exon 14 skipping mutations <u>David Planchard</u> , Villejuif, France	
11:55 - 12:15	Targeting KRAS g12C mutations and beyond <u>Lyudmila Bazhenova</u> , La Jolla, United States of America	
12:15 - 12:35	HER2 alterations: Past, present and future <u>Antonio Passaro</u> , Milan, Italy	
12:35 - 12:45	Q&A	
11:15 - 12:45	Type: Educational session Title: Peri-operative strategies in early stage NSCLC with IO and targeted therapies Moderation: JORDI REMON MASIP, France; Leah Backhus, United States of America	Auditorium 1
11:15 - 11:30	Peri-operative TKI in EGFR mutant tumours and beyond <u>Jordi Remon Masip</u> , Villejuif, France	
11:30 - 11:45	Lights and shadows for the neoadjuvant ICI strategy <u>Lizza Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, Netherlands	
11:45 - 12:00	Lights and shadows for the adjuvant ICI strategy <u>Jessica Menis</u> , Verona, Italy	
12:00 - 12:15	Biological insights for selection of peri-operative strategies <u>Giannis Mountzios</u> , Athens, Greece	
12:15 - 12:30	Surgical perspective on peri-operative treatment and outcomes in the era of immunotherapy <u>Leah Backhus</u> , Stanford, United States of America	
12:30 - 12:45	Q&A	

12:45 - 13:30	Type: Young Oncologists session Title: YO Vesalius Talk - Dare to lead: How to become a leader in the field of lung cancer Moderation: Elene Mariamidze, Georgia; Kok Haw Jonathan Lim, United Kingdom	Foyer
12:45 - 12:45	Panellist <u>Fiona Blackhall</u> , Manchester, United Kingdom	
12:45 - 12:45	Panellist <u>Noemi Reguart Aransay</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, Spain	
12:45 - 12:45	Panellist <u>Charles Rudin</u> , Memorial Sloan Kettering Cancer Center, New York, United States of America	
13:30 - 15:00	Type: Industry Satellite Symposium Title: Amgen - Advancing the treatment landscape for lung cancer with new targets Moderation: Sanjay Popat, United Kingdom	Auditorium 4
13:30 - 13:40	Therapeutic targets for the treatment of lung cancer <u>Sanjay Popat</u> , London, United Kingdom	
13:40 - 14:10	Improving patient outcomes in KRAS G12C mutant NSCLC <u>Hervé Lena</u> , Rennes, France	
14:10 - 14:20	New therapeutic targets for advanced squamous NSCLC <u>Sanjay Popat</u> , London, United Kingdom	
14:20 - 14:40	Targeting DLL3 with T cell engaging therapies in SCLC <u>Anne-Marie Dingemans</u> , Erasmus MC - University Medical Center, Rotterdam, Netherlands	
14:40 - 14:55	Panel discussion and Q&A	
14:55 - 15:00	Summary and close <u>Sanjay Popat</u> , London, United Kingdom	

13:30 - 15:00	Type: Industry Satellite Symposium Title: Janssen Pharmaceuticals - Exploring clinical perspectives in advanced EGFR-mutant NSCLC: How far we have come Moderation: Alfredo Addeo, Switzerland; Enriqueta Felip, Spain	Auditorium 2
13:30 - 13:35	Welcome and introduction <u>Alfredo Addeo</u> , Geneva, Switzerland	
13:35 - 14:05	Translating data into clinical practice in EGFR-mutant NSCLC <u>Zofia Piotrowska</u> , Boston, United States of America	
14:05 - 14:35	Practical data applications in EGFR exon20ins-mutant NSCLC <u>Nicolas Girard</u> , Institut Curie, Paris, France	
14:35 - 15:00	Q&A and closing remarks <u>Enriqueta Felip</u> , Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain	

15:10 - 16:40	Type: Proffered Paper session Title: Proffered Paper 2 Moderation: Martin Reck, Germany; Noemi Reguart Aransay, Spain	Auditorium 1
15:10 - 15:22	840 - Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816 <u>Nicolas Girard</u> , Institut Curie, Paris, France	
15:22 - 15:34	50 - Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: longer follow-up results from the Phase 3 EMPOWER-Lung 3 trial <u>Tamta Makharadze</u> , LTD High Technology Hospital Medical Center, Batumi, Georgia	
15:34 - 15:45	Invited Discussant 840 and 50 <u>Antonio Passaro</u> , Milan, Italy	
15:45 - 15:55	Q&A	
15:55 - 16:07	60 - CONTACT-01: Efficacy and safety from a Ph 3 study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy <u>Joel Neal</u> , Stanford, United States of America	
16:07 - 16:19	1610 - RESILIENT Part 2: A Randomized, Open-label Phase 3 Study of Liposomal Irinotecan versus Topotecan in Adults with Relapsed Small Cell Lung Cancer (SCLC) <u>Charles Rudin</u> , Memorial Sloan Kettering Cancer Center, New York, United States of America	
16:19 - 16:30	Invited Discussant 60 and 1610 <u>Enriqueta Felip</u> , Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain	
16:30 - 16:40	Q&A	
16:40 - 17:00	Type: Coffee break Title: Coffee break	Exhibition and Poster area

17:00 - 17:50	Type: Mini Oral session Title: Mini Oral 1 Moderation: Navneet Singh, India; Fernando Lopez-Rios, Spain	Auditorium 4
17:00 - 17:05	7MO - Sotorasib in KRAS G12C-mutated advanced non-small cell lung cancer (aNSCLC): overall survival (OS) data from the global expanded access program (EAP study-436) <u>Natalie Maimon</u> , Meir Medical Center, Sackler School of Medicine, Orbassano, Italy	
17:05 - 17:10	8MO - Adagrasib (MRTX849) in Patients With Advanced/Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer (NSCLC): Preliminary Analysis of Mutation Allele Frequency <u>Pasi Jänne</u> , Boston, United States of America	
17:10 - 17:15	143MO - Risk of Lung Cancer Among Current Smokers by Pack-Year Smoking: A Cohort Study with 23 Years of Follow-up <u>Joel Nations</u> , Washington, United States of America	
17:15 - 17:25	Invited Discussant 7MO, 8MO and 143MO <u>Navneet Singh</u> , Chandigarh, India	
17:25 - 17:30	9MO - Profile of immunorecognition related markers including HLA-1 expression to predict response to immunocheckpoint inhibitors in non-small cell lung cancer <u>Maria Saigi Morgui</u> , Badalona, Spain	
17:30 - 17:35	145MO - Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study <u>David Carbone</u> , Columbus, United States of America	
17:35 - 17:45	Invited Discussant 9MO and 145MO <u>Fernando Lopez-Rios</u> , Madrid, Spain	

17:00 - 18:00	Type: Multidisciplinary Interactive session Title: Optimal duration of adjuvant TKI Moderation: Natasha Leighl, Canada; Helena A. Yu, United States of America	Auditorium 1
17:00 - 17:15	Case presentation of young patient with EGFR-mutant resected NSCLC (stage pT2pN1) <u>Alfredo Addeo</u> , Geneva, Switzerland	
17:15 - 17:30	Adjuvant TKI for 3 years or less <u>Helena A. Yu</u> , Memorial Sloan Kettering Cancer Center, New York, United States of America	
17:30 - 17:45	Adjuvant TKI for more than 3 years <u>Natasha Leighl</u> , Princess Margaret Cancer Centre, Toronto, Canada	
17:45 - 18:00	Discussion	
17:00 - 18:00	Type: Controversy session Title: Is there a place for conformal PORT in 2023? Moderation: Silvia Novello, Italy	Auditorium 2
17:00 - 17:10	Introduction and first vote <u>Silvia Novello</u> , Università degli Studi Di Torino – San Luigi Hospital, Orbassano, Italy	
17:10 - 17:30	Yes <u>Dirk De Ruysscher</u> , Maastric Clinic, Maastricht, Netherlands	
17:30 - 17:50	No <u>Cécile Le Pechoux</u> , Villejuif, France	
17:50 - 18:00	Second vote and conclusions <u>Silvia Novello</u> , Università degli Studi Di Torino – San Luigi Hospital, Orbassano, Italy	

18:15 - 19:15	Type: Industry Satellite Symposium Title: Sanofi and Regeneron - Overcoming unmet needs with immunotherapy in locally advanced NSCLC Moderation: Luis Paz-Ares, Spain	Auditorium 2
18:15 - 18:20	Welcome and introduction <u>Luis Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
18:20 - 18:35	Defining unmet need in locally advanced disease <u>Nicolas Girard</u> , Institut Curie, Paris, France	
18:35 - 18:50	Review of immunotherapy data in locally advanced disease <u>Luis Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
18:50 - 19:05	Locally advanced case study discussion <u>Ewa Kalinka-Warzocho</u> , Łódź, Poland	
19:05 - 19:15	Panel discussion	
18:15 - 19:45	Type: Industry Satellite Symposium Title: Daiichi Sankyo and AstraZeneca - Addressing the unmet need in mNSCLC: Treating progression after immunochemotherapy Moderation: Maurice Perol, France	Auditorium 4
18:15 - 18:20	Welcome and introduction <u>Maurice Perol</u> , Lyon, France	
18:20 - 18:40	Strategies for treating patients with progression after immunochemotherapy <u>Maurice Perol</u> , Lyon, France	
18:40 - 19:00	Antibody-drug conjugates: Current perspectives <u>Antonio Passaro</u> , Milan, Italy	
19:00 - 19:20	Antibody-drug conjugates: Future considerations <u>Enriqueta Felip</u> , Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain	
19:20 - 19:45	Audience Q&A and closing remarks	

31.03.2023

08:15 - 09:15 **Type: Controversy session** **Auditorium 2**
Title: Adjuvant chemotherapy in EGFR mutated NSCLC
Moderation: Laura Mezquita, Spain

08:15 - 08:25 **Introduction and first vote**
Laura Mezquita, Barcelona, Spain

08:25 - 08:45 **Yes**
Benjamin Besse, Institut Gustave Roussy, Villejuif, France

08:45 - 09:05 **No**
Alessandra Curioni-Fontecedro, University of Fribourg, Fribourg, Switzerland

09:05 - 09:15 **Second vote and conclusions**
Laura Mezquita, Barcelona, Spain

08:15 - 09:15 **Type: Mini Oral session** **Auditorium 4**
Title: Mini Oral 2
Moderation: Marina Garassino, United States of America; Nir Peled, Israel

08:15 - 08:20 **114MO - First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3**
Ewa Kalinka-Warzocha, Łódź, Poland

08:20 - 08:25 **10MO - EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%: 3-year update**
Saadettin Kilickap, Istinye University Faculty of Medicine, Istanbul, Turkey

08:25 - 08:30 **11MO - Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors**
Margarita Majem Tarruella, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

08:30 - 08:35 **12MO - Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) & tremelimumab (T), in the phase 3 POSEIDON study**
Niels Reinmuth, Gauting, Germany

08:35 - 08:45 **Invited Discussant 114MO, 10MO, 11MO and 12MO**
Nir Peled, Shaare Zedek Medical Center, Jerusalem, Israel

08:45 - 08:50 **13MO - Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab & chemotherapy in patients with CEACAM5-positive**

nonsquamous NSCLC (CARMEN-LC05 phase 2 study)

Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain

- 08:50 - 08:55 **14MO - Updated Efficacy and Safety of Taletrectinib in Patients (pts) with ROS1+ Non-Small Cell Lung Cancer (NSCLC)**
Wei Li, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China
- 08:55 - 09:00 **15MO - Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib**
Martin Hoejgaard, Copenhagen, Denmark
- 09:00 - 09:05 **16MO - Clinical impact of plasma EGFR analysis: results from the ETOP-BOOSTER randomized phase II trial**
Ross Soo, Singapore, Singapore
- 09:05 - 09:15 **Invited Discussant 13MO, 14MO, 15MO and 16MO**
Marina Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, United States of America

08:30 - 10:00	Type: Special session Title: Harnessing the power of screening in lung cancer (Cancer nursing session)	Auditorium 15
	Moderation: Nikolina Dodlek, Croatia; Morten Quist, Denmark	

- 08:30 - 08:50 **Lung cancer screening in Europe: New screening recommendations and challenges**
Lavinia Magee, Cambridge, United Kingdom
- 08:50 - 09:10 **Establishing a nationwide lung cancer screening programme: The case of Croatia**
Sandra Karabatic, Zagreb, Croatia
- 09:10 - 09:30 **Artificial intelligence in screening mammography**
Andreas Charalambous, Limassol, Cyprus
- 09:30 - 09:50 **The role of advanced nurses in providing smoking cessation care in screening programmes: Current challenges and future opportunities**
- 09:50 - 10:00 **Q&A and live discussion**

09:30 - 10:00	Type: Keynote lecture Title: Equity and sustainability in lung cancer care in resource-restricted contexts Moderation: Anne-Marie Baird, Ireland	Auditorium 1
09:30 - 09:35	Introduction <u>Anne-Marie Baird</u> , Dublin, Ireland	
09:35 - 10:00	Equity and sustainability in lung cancer care in resource-restricted contexts <u>Clarissa Maria De Cerqueira Mathias</u> , Oncoclinicas, Salvador, Brazil	
10:00 - 10:30	Type: Coffee break Title: Coffee break	Exhibition and Poster area
10:30 - 12:00	Type: Special session Title: Optimising cancer outcomes through supportive care (Cancer nursing session) Moderation: Andreas Charalambous, Cyprus; Maria Ftanou, Australia	Auditorium 15
10:30 - 10:50	Psychological impacts of being treated with novel therapies <u>Maria Ftanou</u> , Melbourne, Australia	
10:50 - 11:10	Improving lung cancer outcomes through prehabilitation: Are we there yet? <u>Morten Quist</u> , Copenhagen, Denmark	
11:10 - 11:30	Immunotherapy in lung cancer patients: Current overview and future perspectives <u>Nikolina Dodlek</u> , Osijek, Croatia	
11:30 - 11:50	Being an informal carer: Overcoming challenges to their own health and quality of life and facilitating the role <u>Joana Vicente</u> , Linnaeus University, Kalmar, Sweden	
11:50 - 12:00	Q&A and live discussion	

10:30 - 12:00	Type: Educational session Title: Present and future of multimodality strategies in stage III NSCLC Moderation: Matthias Guckenberger, Switzerland; Anne-Marie Dingemans, Netherlands	Auditorium 1
----------------------	--	---------------------

10:30 - 10:50	Immunotherapy mono and combinations in unresectable stage III NSCLC <u>Sophie Guillerm</u> , Paris, France	
10:50 - 11:10	De-escalation strategies in unresectable stage III NSCLC <u>Matthias Guckenberger</u> , University Hospital Zurich, Zurich, Switzerland	
11:10 - 11:30	Can we turn unresectable into resectable stage III NSCLC? <u>Johan Vansteenkiste</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium	
11:30 - 11:50	The role of biomarkers in stage III NSCLC <u>Anne-Marie Dingemans</u> , Erasmus MC - University Medical Center, Rotterdam, Netherlands	
11:50 - 12:00	Q&A	

10:30 - 12:00	Type: Educational session Title: Screening and early detection Moderation: Nir Peled, Israel; Luis Montuenga, Spain	Auditorium 4
----------------------	---	---------------------

10:30 - 10:50	Robustness of LDCT program for early detection of lung cancer <u>Harry De Koning</u> , Erasmus University Medical Center, Rotterdam, Netherlands	
10:50 - 11:10	Steps to implement LDCT programme <u>Silvia Novello</u> , Università degli Studi Di Torino - San Luigi Hospital, Orbassano, Italy	
11:10 - 11:30	Biomarkers to support screening <u>Luis Montuenga</u> , Pamplona, Spain	
11:30 - 11:50	Novel liquid biomarkers for screening lung cancer <u>Christian Rolfo</u> , New York, United States of America	
11:50 - 12:00	Q&A	

10:30 - 12:00	Type: Special Symposium Title: New therapeutic classes: ADCs, bispecifics and novel IO agents Moderation: Fiona Blackhall, United Kingdom; Pedro Romero, Switzerland	Auditorium 2
10:30 - 10:50	Antibody drug conjugates <u>Daniel Shao Weng Tan</u> , NCCS - National Cancer Centre Singapore, Singapore, Singapore	
10:50 - 11:10	Bispecific antibodies <u>Fiona Blackhall</u> , Manchester, United Kingdom	
11:10 - 11:30	Novel checkpoints <u>Jarushka Naidoo</u> , Beaumont Hospital, Dublin, Ireland	
11:30 - 11:50	Cancer vaccines <u>Pedro Romero</u> , Lausanne, Switzerland	
11:50 - 12:00	Q&A	
12:00 - 12:45	Type: Poster Display session Title: Poster Display session	Exhibition and Poster area
12:00 - 12:00	17P - Treatment Sequence for Non-small-cell Lung Cancer with Brain Oligometastases does not Impact Overall Survival <u>Arvind Kumar</u> , New York, United States of America	
12:00 - 12:00	18P - Stereotactic radiotherapy(SRT) in combination with Aumolertinib to treat intracranial oligometastatic Non-Small Cell Lung Cancer (NSCLC): An update of the phase II, prospective study <u>Jiayan Chen</u> , Shanghai, China	
12:00 - 12:00	19P - Mortality Among EGFR-Mutated Advanced NSCLC Patients After Frontline Osimertinib Treatment: A Real-World, US Attrition Analysis <u>Nicolas Girard</u> , Institut Curie, Paris, France	
12:00 - 12:00	20P - Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small-cell lung cancer with central nervous system metastases in a multi-center, phase 2 umbrella trial (CTONG1702) <u>Si-Yang Liu</u> , Guangzhou, China	
12:00 - 12:00	21P - Bevacizumab plus Atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR Tyrosine Kinase Inhibitor: the BACH-NET study. <u>Giulia Pasello</u> , Padova, Italy	

- 12:00 - 12:00 **22P - Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: a single-arm, multicenter, phase II trial**
Huajun Chen, Guangzhou, China
- 12:00 - 12:00 **23P - Impact of PDL1 expression on Outcomes of patients with EGFR mutant NSCLC treated with EGFR TKIs: first results of the POET study.**
Lorenzo Belluomini, Verona, Italy
- 12:00 - 12:00 **24P - Efficacy and safety of 1st generation EGFR TKI retreatment in EGFR mutation positive, T790M negative patients who previously treated with 1st or 2nd generation EGFR TKI and cytotoxic chemotherapy**
Sung Yong Lee, Seoul, Korea, Republic of
- 12:00 - 12:00 **25P - Furmonertinib Plus Icotinib for First-Line Treatment of EGFR-mutated Non-Small Cell Lung Cancer**
Hualin Chen, Zhanjiang, China
- 12:00 - 12:00 **26P - Real-World Use of Tyrosine Kinase Inhibitors (TKI) in Epidermal Growth Factor Receptor mutated (EGFRm) Advanced Non-Small Cell Lung Cancer (NSCLC) in Nine Countries**
Jens Samol, Singapore, Singapore
- 12:00 - 12:00 **27P - Amivantamab Versus Alternative Real-World Anti-Cancer Therapies in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in the US and Europe**
Nicolas Girard, Institut Curie, Paris, France
- 12:00 - 12:00 **28P - Generation and validation of a predictive model using pretreatment clinical factors for estimating survival and T790M mutation in EGFR-Mutated non-small cell lung cancer in Taiwan**
Chien-Chung Lin, Tainan City, Taiwan
- 12:00 - 12:00 **29P - Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors.**
Shang-Gin Wu, Taipei, Taiwan
- 12:00 - 12:00 **30P - Real-world disease characteristics and treatment patterns in patients with advanced non-small cell lung cancer and EGFR in Brazil and Taiwan**
Hollie Bailey, Bollington, United Kingdom
- 12:00 - 12:00 **31P - EGFR mutation rate and spectrum in Ukrainian patients with advanced NSCLC: relation to gender and PD-L1 expression**
Sofiia Livshun, Kyiv, Ukraine
- 12:00 - 12:00 **32P - Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI**

Jingjing Wang, Beijing, China

- 12:00 - 12:00 **33P - Real-world experience of MET TKI-induced peripheral edema**
Roberto Ferrara, Milan, Italy
- 12:00 - 12:00 **34P - Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC**
Frank Griesinger, Oldenburg, Germany
- 12:00 - 12:00 **35P - Drug treatment management of advanced ALK-positive non-small cell lung cancer in Spain. A real-world cross-sectional analysis**
Maria Eugenia Olmedo Garcia, Madrid, Spain
- 12:00 - 12:00 **36P - Prevalence, clinical characteristics, and treatment outcomes of patients with BRAF-mutated advanced NSCLC in China: a real-world multi-center study**
Bo Jia, Beijing, China
- 12:00 - 12:00 **37P - Pralsetinib in acquired RET fusion positive advanced non-small cell lung cancer patients after resistance to EGFR/ALK-TKI: a China multi-center, real-world data(RWD) analysis**
Jie Hu, Shanghai, China
- 12:00 - 12:00 **38P - Matching-adjusted indirect comparison (MAIC) of treatment outcomes for selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC)**
Maximilian Hochmair, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria
- 12:00 - 12:00 **39P - Preliminary clinical investigations and mechanism exploration of furmonertinib in NSCLC with EGFR Exon 20 insertion**
Xiao Zhang, Zhengzhou, China
- 12:00 - 12:00 **40P - Updated data from the Phase I Beamion Lung 1 trial of BI 1810631, a HER2 TKI, in patients (pts) with advanced solid tumours with HER2 aberrations**
Frans Opdam, Amsterdam, Netherlands
- 12:00 - 12:00 **41P - Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)**
Hossein Borghaei, Philadelphia, United States of America
- 12:00 - 12:00 **42P - Pembrolizumab vs Chemotherapy in Chinese Patients With Non-Small-Cell Lung Cancer (NSCLC) and PD-L1 TPS ≥1%: 5-Year Update From KEYNOTE-042**
Yi-Long Wu, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
- 12:00 - 12:00 **43P - Camrelizumab plus famitinib as first-line treatment in advanced NSCLC**

patients with PD-L1 TPS ≥1%: a report from a multicenter, open-label, phase II basket trial

Shengxiang Ren, Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, China

- | | |
|---------------|---|
| 12:00 - 12:00 | <p>44P - Dostarlimab (Dos) or Pembrolizumab (Pem) + Chemotherapy (CT) in Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Patient (Pt) and Disease Characteristics Subgroup Analyses From the PERLA Trial</p> <p><u>Ana Laura Ortega Granados</u>, Jaén, Spain</p> |
| 12:00 - 12:00 | <p>45P - DCVAC/LuCa with chemotherapy in patients with stage IV, non-squamous NSCLC without EGFR/ALK aberrations: Five-Year Survival Update</p> <p><u>Xuxinyi Ling</u>, Shanghai, China</p> |
| 12:00 - 12:00 | <p>46P - Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study</p> <p><u>Reiko Matsuzawa</u>, Nagoya, Japan</p> |
| 12:00 - 12:00 | <p>47P - Timing of Radiotherapy Affects Outcomes of Patients with Metastatic NSCLC Who Receive Immunotherapy</p> <p><u>Shenduo Li</u>, Jacksonville, United States of America</p> |
| 12:00 - 12:00 | <p>48P - Characteristics and treatment patterns of patients with advanced or metastatic non-small cell lung cancer managed with first-line immuno-oncology strategies in Greece: Interim results of a real-world prospective study (IO-HORIZON)</p> <p><u>Helena Linardou</u>, Metropolitan Hospital, Athens, Greece</p> |
| 12:00 - 12:00 | <p>49P - Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation</p> <p><u>Ana Baramidze</u>, Research Institute of Clinical Medicine, Todua Clinic, Tbilisi, Georgia</p> |
| 12:00 - 12:00 | <p>50P - Patient-reported outcomes in non-small cell lung cancer patients receiving immunotherapy monotherapy: analysis from Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) pragmatic clinical trial</p> <p><u>Bolun Liu</u>, Mankato, United States of America</p> |
| 12:00 - 12:00 | <p>51P - Real world outcomes of immunotherapy in non-small cell lung cancer - a population-based cohort study in Sweden</p> <p><u>Lars Gunnar Wagenius</u>, Stockholm, Sweden</p> |
| 12:00 - 12:00 | <p>52P - Real-world versus clinical trial outcomes of pembrolizumab plus chemotherapy in patients with stage IV non-squamous non small cell lung cancer</p> |

Marjon Verschueren, Nieuwegein, Netherlands

- 12:00 - 12:00 **53P - Real-World Outcomes of First-Line Pembrolizumab (Pem) for Metastatic Non-Small Cell Lung Cancer (mNSCLC) with ≥50% Expression of Programmed Cell Death-Ligand 1 (PD-L1). A multicentre retrospective study**
Javier Perea, Valencia, Spain
- 12:00 - 12:00 **54P - Real-world efficacy of immunotherapy plus anti-angiogenesis versus immunotherapy monotherapy as second-line or later treatment in advanced non-small cell lung cancer**
Yao Zhang, Shanghai, China
- 12:00 - 12:00 **55P - Real-world monitoring of hybrid dosing of pembrolizumab in stage IV non-small cell lung cancer in the Netherlands**
Esther Dronkers, Amsterdam, Netherlands
- 12:00 - 12:00 **56P - Pooled analysis of 4 studies evaluating weekly oral vinorelbine in patients with locally advanced or metastatic non-small-cell lung cancer.**
Christos Chouaid, Créteil, France
- 12:00 - 12:00 **57P - A study of gemcitabine-cisplatin vs paclitaxel- carboplatin chemotherapy in patients with advanced squamous cell carcinoma of the lung:**
Teena Rajan, Chennai, India
- 12:00 - 12:00 **58P - Treatment combinations in non-driver mutated mNSCLC: A systematic review and Bayesian network meta-analysis**
Preetha Umesh, New Delhi, India
- 12:00 - 12:00 **59P - Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC.**
Alberto Servetto, Università degli Studi di Napoli Federico II, Napoli, Italy
- 12:00 - 12:00 **60P - Comparison of metastasis patterns and prognosis of advanced old NSCLC patients by age groups: a SEER database analysis**
Yang Lingqi, Tianjin, China
- 12:00 - 12:00 **61P - Early palliative care in Patients with Non-Small-Cell Lung Cancer: a 36-weeks randomised controlled trial in China**
Mengting Chen, Chongqing, China
- 12:00 - 12:00 **62P - Predictive value of Combined Positive Score (CPS) and Tumor Proportion Score (TPS) for immunotherapy response in advanced Non-Small Cell Lung Cancer (NSCLC)**
Ezgi Ulas, Amsterdam, Netherlands
- 12:00 - 12:00 **63P - Inflammatory indexes and treatment response as correlates of effectiveness pembrolizumab in patients with PD-L1 ≥50%- data from the real-life**

practice

Magdalena Knetki-Wroblewska, Warsaw, Poland

- 12:00 - 12:00 **64P - Pretreatment predictive score for metastatic non-small cell lung cancer patients treated with immunotherapy**
Aram Musaelyan, Saint-Petersburg, Russian Federation
- 12:00 - 12:00 **65P - Correlation of overall survival and surrogate endpoints in advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a trial-level analysis.**
Fabio Salomone, Napoli, Italy
- 12:00 - 12:00 **66P - Outcome predictors for Pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)**
Lodovica Zullo, Genova, Italy
- 12:00 - 12:00 **67P - Blood cell gene expression and clinical characteristics in advanced non-small-cell lung cancer with immune-related adverse events**
Lea Daniello, Heidelberg, Germany
- 12:00 - 12:00 **69P - THE EFFECT OF INFLAMMATORY-NUTRITIONAL PROGNOSTIC SCORING SYSTEM (INPS) ON TREATMENT RESPONSE AND PROGNOSIS IN PATIENTS WITH METASTATIC NSCLC AS SECOND LINE TREATMENT WITH NIVOLUMAB**
Merve Keskinilic, Atlanta, United States of America
- 12:00 - 12:00 **70P - Impact of TP53/KRAS mutations on Overall Survival of Metastatic non-Small Cell Lung Cancer Patients (pts) Treated with Systemic First-line Therapy**
Silvia Rubio Novella, Castellon de la Plana, Spain
- 12:00 - 12:00 **71P - Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)**
Anas Gazzah, Institut Gustave Roussy, Villejuif, Cedex, France
- 12:00 - 12:00 **72P - Association of Receptor activator of nuclear factor kappa-_l ligand (RANKL) and Epidermal Growth Factor Receptor (EGFR) gene expression with bone metastases (mets) in patients (pts) with metastatic Non-Small Cell Lung Cancer (mNSCLC)**
Anita Brouns, Heerlen, Netherlands
- 12:00 - 12:00 **73P - Qualitative Research to Evaluate Perceptions Around Biomarker Testing and Patient-Reported Outcomes (PROs) for Use in Studies of Non-Small Cell Lung Cancer (NSCLC)**
Marcia Horn, Phoenix, United States of America
- 12:00 - 12:00 **74P - Non Small Cell Lung Cancer (NSCLL) predictors of response to immunotherapy (ICI): LIPI index and immune-related toxicity.**
Alba Moratiel Pellitero, Zaragoza, Spain

- 12:00 - 12:00 **75TiP - A multicenter, open-label, phase 2 trial evaluating the safety and efficacy of folate receptor alpha (FR_α) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC)**
David Planchard, Villejuif, France
- 12:00 - 12:00 **76TiP - Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in metastatic Lung Cancer**
Ismaell Massalha, Beer Sheva, Israel
- 12:00 - 12:00 **77TiP - A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors including Non-Small Cell Lung Cancer**
Mariam Alexander, MUSC Health University Medical Center, Mount Pleasant, United States of America
- 12:00 - 12:00 **78TiP - Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous NSCLC with/without STK11 mutations.**
Rajwanth Veluswamy, New York, United States of America
- 12:00 - 12:00 **79TiP - Progress of a Phase I Trial (TOTEM) of Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR Mutant NSCLC**
Andres Aguilar Hernandez, Barcelona, Spain
- 12:00 - 12:00 **80TiP - High-dose Aumolertinib Versus Osimertinib in EGFR T790M+ NSCLC Patients With Brain Metastases (ATTACK)**
Shun Lu, Shanghai, China
- 12:00 - 12:00 **81TiP - NVL-655, a Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor, in Patients with Advanced ALK-Positive Solid Tumors: The Phase 1/2 ALKOVE-1 Study**
Melissa Johnson, Nashville, United States of America
- 12:00 - 12:00 **82TiP - A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies**
Andrew Gianoukakis, LA, United States of America
- 12:00 - 12:00 **83TiP - A Phase 2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone and in Combination with Nivolumab in in Adult Patients with Metastatic NSCLC Who Had Prior Disease Progression on or Are Intolerant to a PD-1/L1, EGFR, or ALK Inhibitor**
Grace Dy, Buffalo, United States of America
- 12:00 - 12:00 **85P - The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on patients with stage I non-small cell lung cancer harboring sensitive EGFR**

mutations

Yu Jiang, Guangzhou, China

- | | |
|---------------|---|
| 12:00 - 12:00 | 86P - KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma
<u>Daniele Marinelli</u> , Rome, Italy |
| 12:00 - 12:00 | 87P - Prognostic models of recurrence free survival in non-small cell lung cancer
<u>Kieran Palmer</u> , London, United Kingdom |
| 12:00 - 12:00 | 88P - Quantitative CT parameters in predicting the degree of risk of solitary pulmonary nodules
<u>Long Jiang</u> , Shanghai, China |
| 12:00 - 12:00 | 89P - A clinical- and biological-based nomogram to predict unforeseen nodal metastases in clinically node-negative, radically resected lung adenocarcinoma
<u>Filippo Tommaso Gallina</u> , Rome, Italy |
| 12:00 - 12:00 | 90P - Cell-free DNA as a predictive and prognostic marker in adjuvant-treated non-small cell lung cancer
<u>Eider Azkona</u> , Barakaldo, Spain |
| 12:00 - 12:00 | 91P - Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study
<u>Steven Lin</u> , Cambridge, United States of America |
| 12:00 - 12:00 | 92P - Predictors, surrogate and patient-reported outcomes in neoadjuvant immunotherapy for lung cancer: A single center retrospective study
<u>Luca Bertolaccini</u> , Milan, Italy |
| 12:00 - 12:00 | 93P - A phase II study of camrelizumab plus chemotherapy in patients with medically inoperable early-stage non-small cell lung cancer
<u>Changli Wang</u> , Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China |
| 12:00 - 12:00 | 94P - Neoadjuvant tislelizumab combined with (nab)-paclitaxel plus platinum-based chemotherapy for patients with stage IIA&#x2013;IIIB squamous NSCLC: A real-world retrospective study
<u>Xiaojie Huang</u> , Hangzhou, China |
| 12:00 - 12:00 | 95P - Neoadjuvant treatment pattern and association between real-world event-free survival (rwEFS) and overall survival (OS) in patients (pts) with resected early-stage non-small cell lung cancer (eNSCLC)
<u>Jessica Donington</u> , Chicago, United States of America |
| 12:00 - 12:00 | 96P - Characteristics of patients with resectable non-metastatic non-small cell lung cancer treated with or without neoadjuvant therapy in Europe and Canada: |

A real-world survey

Hollie Bailey, Bollington, United Kingdom

- 12:00 - 12:00 **97P - Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I–III non-small cell lung cancer with high-risk pathological factors**
Xiaohan Chen, Ningbo, China
- 12:00 - 12:00 **98P - Adjuvant aumolertinib in resected EGFR-mutated non-small cell lung cancer: A multiple-center real-world experience**
Qingyi Zhang, Hangzhou, China
- 12:00 - 12:00 **99P - The optimal treatment for patients with stage I non-small cell lung cancer: Minimally invasive lobectomy or stereotactic ablative radiotherapy?**
Julianne De Ruiter, Amsterdam, Netherlands
- 12:00 - 12:00 **100P - Effects of U.S. insurance type on 5-year all-cause mortality after robotic-assisted pulmonary lobectomy for lung cancer**
Allison Dumitriu Carcoana, Tampa, United States of America
- 12:00 - 12:00 **101P - Evidence base for exercise prehabilitation suggests favourable outcomes for patients undergoing surgery for non-small cell lung cancer despite being of low therapeutic quality: A systematic review and meta-analysis**
Melissa Voorn, Venlo, Netherlands
- 12:00 - 12:00 **102P - A qualitative stakeholder analysis of beliefs, facilitators, and barriers for a feasible prehabilitation program before lung cancer surgery**
Melissa Voorn, Venlo, Netherlands
- 12:00 - 12:00 **103P - Patient and clinician perspectives on adjuvant treatment in early-stage non-small cell lung cancer (NSCLC): Qualitative results**
Hannah Collacott, Bethesda, United States of America
- 12:00 - 12:00 **104TiP - MRD Evaluation of Aumolertinib in EGFR Mutation-positive stage IB and stage IA2-3 NSCLC After Complete Surgical Resection: A Multicenter, Open-label, Single-arm Study (ASSIST)**
Chao Cheng, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- 12:00 - 12:00 **105P - Development and assessment of artificial intelligence detection of lung nodules on chest roentgenograms**
Mitsunori Higuchi, Aizuwakamatsu, Japan
- 12:00 - 12:00 **106P - AI negative predictive performance exceeds that of radiologists in volumetric based risk stratification of lung nodules detected at baseline in a lung cancer screening population**
Harriet Lancaster, Groningen, Netherlands
- 12:00 - 12:00 **107P - Artificial intelligence-based volumetric classification of pulmonary**

nodules in Chinese baseline lung cancer screening population (NELCIN-B3)

Yifei Mao, Groningen, Netherlands

12:00 - 12:00 **108P - Optimization of automatic emphysema detection in lung cancer screening dataset**

Hailan Liu, Groningen, Netherlands

12:00 - 12:00 **109P - Setting up 4D-CT based Image Guided Radiotherapy (IGRT) for locally advanced lung cancer: Is it safe to reduce PTV margin for dosimetric benefit?**

Animesh Saha, Kolkata, India

12:00 - 12:00 **110P - Volumetric tumor volume doubling time in lung cancer: a systematic review and meta-analysis**

Beibei Jiang, Rotterdam, Netherlands

12:00 - 12:00 **111P - Application of radiomics signatures and unidimensional vs volumetric measurement of early tumor growth dynamics (TGD) to predict first-line treatment outcomes in patients with stage IV non-small cell lung cancer (NSCLC)**

Lawrence Schwartz, New York, United States of America

12:00 - 12:00 **112P - Retrospective analysis of the use of immunohistochemistry for the diagnosis of adenosquamous carcinoma of the lung in a Dutch national cohort**

Shay Soekhoe, Rotterdam, Netherlands

12:00 - 12:00 **113P - Clinical Overstaging in Pathologic Stage I Non-Small Cell Lung Cancer: Prognostic Implications**

Nathaniel Deboever, Houston, United States of America

12:00 - 12:00 **115P - SALVAGE SURGERY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER**

Raphael Werner, Zurich, Switzerland

12:00 - 12:00 **116P - Survival outcome of chemotherapy in stage IIIA and IIIB non-small cell lung cancer**

Amr Aly, Ismailia, Egypt

12:00 - 12:00 **117P - Survival outcomes of surgery-based treatment or definitive chemoradiation with immunotherapy consolidation in stage IIIA NSCLC in the immune therapy era: An NCDB analysis.**

Janeesh Sekkath Veedu, Lexington, United States of America

12:00 - 12:00 **118P - High dose chemo-radio-immunotherapy for NSCLC III: ESR/ATS thresholds for DLCO correlate with radiation dosimetry and predict pneumonitis**

Franz Zehentmayr, Salzburg, Austria

12:00 - 12:00

119P - Prospective trial of immuno-(chemo)therapy (IO) prior to resection, definitive chemo-radiotherapy, or palliative therapy in patients with borderline resectable non-small cell lung cancer (NSCLC) including oligometastatic disease (KOMPASSneo)

Martin Faehling, Esslingen am Neckar, Germany

12:00 - 12:00 **120P - Neoadjuvant Immunochemotherapy of Pembrolizumab plus Chemotherapy in Resectable Non-Small Cell Lung Cancer**

Yulong Chen, Tianjin, China

12:00 - 12:00 **121P - neoadjuvant Sintilimab and Anlotinib combined with chemotherapy for resectable NSCLC: A prospective, single arm, multicenter study**

Xiaolong Yan, Xi'an, China

12:00 - 12:00 **122P - Comparison of the efficacy of neoadjuvant Pembrolizumab vs Sintilimab combination with chemotherapy in resectable lung cancer: a multicenter propensity score matching study**

Xiaolong Yan, Xi'an, China

12:00 - 12:00 **123P - Second Progression-Free Survival (PFS2) after First Progression in Patients Receiving PACIFIC Regimen: an Exploratory Analysis of the Blue Sky Observational Study.**

Andrea Riccardo Filippi, Pavia, Italy

12:00 - 12:00 **124P - SPOTLIGHT real-world study: outcomes with or without consolidation durvalumab (D) after chemoradiotherapy (CRT) in patients with unresectable Stage III NSCLC**

Ryan Whitaker, Nashville, United States of America

12:00 - 12:00 **125P - Real-world treatment patterns in stage III NSCLC patients: Interim results of a prospective, multicenter, non-interventional study (MOOREA)**

Ligang Xing, Jinan, China

12:00 - 12:00 **126P - chemotherapy and STereotactic Ablative RadioTherapy in NEWly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for concurrEnt RAdio-chemotherapy: sub-analysis and update of START-NEW-ERA non-randomised phase II trial**

Fabio Arcidiacono, Terni, Italy

12:00 - 12:00 **127P - STEREOTACTIC ABLATIVE RADIOTHERAPY AND DURVALUMAB: THE BACKBONE OF UNRESECTABLE LOCALLY ADVANCED NON SMALL CELL LUNG CANCER PATIENTS UNFIT TO CONCURRENT CHEMO-RADIOTHERAPY: RIB OF START-NEW-ERA TRIAL**

Fabio Arcidiacono, Terni, Italy

12:00 - 12:00 **128P - Stereotactic ablative radiotherapy in locally-advanced non-small-cell lung cancer patients: little palliation or big cure? Sub-analysis of START NEW ERA phase II trial**

Fabio Arcidiacono, Terni, Italy

- 12:00 - 12:00 **129P - Adjuvant Therapy for T3 Non-small-cell Lung Cancer with Additional Intrapulmonary Nodules**
Arvind Kumar, New York, United States of America
- 12:00 - 12:00 **130TiP - Adjuvant osimertinib in patients with completely resected, stage IB-IIIB non-small cell lung cancer with uncommon EGFR mutations: A phase 2, open-label, single arm, multicenter, exploratory study**
Chengwu Liu, Sichuan, China
- 12:00 - 12:00 **131TiP - A Phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients (pts) with biomarker-defined locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC)**
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain
- 12:00 - 12:00 **132TiP - Boosting Immune Response with Copanlisib in Locally Advanced Unresectable Non-Small Cell Lung Cancer Starting Durvalumab Consolidation, A Phase Ib study**
Zhonglin Hao, University of Kentucky - Markey Cancer Center, Lexington, United States of America
- 12:00 - 12:00 **133TiP - Neoadjuvant osimertinib followed by sequential definitive radiotherapy and/or surgery in stage III EGFR-mutant NSCLC: An open-label, single-arm, phase II study**
Waleed Kian, Beer Sheva, Israel
- 12:00 - 12:00 **134P - Clinical and Epidemiological Patterns of Pleural Mesothelioma in the United States: Long-Term Data from SEER Database**
Mohamed Ahmed, Benha, Egypt
- 12:00 - 12:00 **135P - Macroscopic complete resection versus non-surgical management for malignant pleural mesothelioma**
Asmaa Ellaithy, Ismailia, Egypt
- 12:00 - 12:00 **136P - Germline testing in a cohort of malignant MESOthelioma (G-MESO)**
Ernest Nadal, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, Spain
- 12:00 - 12:00 **137P - Repurposing drug screen of patient-derived malignant pleural mesothelioma cells reveals potential anti-cancer activity**
Alexander Laure, Fribourg, Switzerland
- 12:00 - 12:00 **138P - Cost-effectiveness of nivolumab and ipilimumab versus chemotherapy (with and without bevacizumab) in patients with unresectable malignant pleural mesothelioma in Switzerland**
Michaela Barbier, Basel, Switzerland

- 12:00 - 12:00 **139P - Gemcitabine As Maintenance Treatment Of Malignant Pleural Mesothelioma (GEMO): Randomized Phase II Study**
Mohamed Emam, Cairo, Egypt
- 12:00 - 12:00 **140P - Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials, with focus on NSCLC**
Antoine Mavrikios, Villejuif, France
- 12:00 - 12:00 **141P - Unveiling the likely pharmacological mechanisms of brigatinib on brain metastasis in ALK+ patients with non-small cell lung cancer: a systems biology and artificial intelligence-based approach**
Enric Carcereny Costa, Badalona, Spain
- 12:00 - 12:00 **142P - Patients with ECOG status 2 should not receive whole brain radiotherapy (WBRT). A prospective cohort study of 294 non-small cell lung cancer (NSCLC) patients with brain metastases (BM).**
Astrid Karlsson, Oslo, Norway
- 12:00 - 12:00 **144P - Exposure- lag response of Surface Net Solar Radiation on Lung Cancer Incidence: A Worldwide Interdisciplinary and Time- series Study**
Xuanzhuang Lu, Guangzhou, China
- 12:00 - 12:00 **146P - The Changing Landscape of Stage-at-Presentation in Lung Cancer in the United States: Long-Term Data from SEER Database**
Mohamed Ahmed, Benha, Egypt
- 12:00 - 12:00 **147P - Changes in demographic and smoking history trends in patients referred to a London Thoracic Malignancy Specialist Centre between 2010-2021. The Guy's Cancer Centre Experience**
Charalampos Gousis, London, United Kingdom
- 12:00 - 12:00 **148P - Education level of lung cancer patients and matched controls in Denmark: Development over time in a nationwide study 1994-2018**
Morten Borg, Vejle, Denmark
- 12:00 - 12:00 **149P - Gender Differences in Non-Small Cell Lung Cancer: A Comparative Analysis of European and Asian Patients**
Aime Giorlando, Buenos Aires, Argentina
- 12:00 - 12:00 **150P - Sex differences in inoperable lung cancer risk and prognosis: evidence from low-income population setting**
Muhammad Rafiqul Islam, Dhaka, Bangladesh
- 12:00 - 12:00 **151P - Molecular epidemiology and real-world outcomes of genomically-matched non-squamous non-small cell lung cancer (nsNSCLC) patients in a diverse Brazilian population**
Rodrigo Dienstmann, São Paulo, Brazil

- 12:00 - 12:00 **152P - Role of occupation in patients with non-small cell lung cancer (NSCLC) in Spain: data from the SCAN study**
Juan Carlos Laguna Montes, Barcelona, Spain
- 12:00 - 12:00 **153P - Molecular Epidemiology of EGFR mutations in NSCLC: a single center experience from India**
Mithua Ghosh, Bangalore, India
- 12:00 - 12:00 **154P - Why is the screening rate in lung cancer still low? A 7-country analysis on the factors impacting adoption**
Charlotte Poon, London, United Kingdom
- 12:00 - 12:00 **155P - Eligibility for lung cancer screening among patients diagnosed with lung cancer in Greece**
Maximilian Anagnostakis, Athens, Greece
- 12:00 - 12:00 **156P - DEVELOPMENT OF A PREDICTIVE MODEL FOR EARLY DETECTION OF LUNG CANCER: SREAL-eLUNG STUDY**
Oscar Jose Juan Vidal, Valencia, Spain
- 12:00 - 12:00 **157P - Building a global evidence map of low-dose CT lung cancer screening implementation: approach and data analysis opportunities**
Eleanor Wheeler, London, United Kingdom
- 12:00 - 12:00 **158P - Lung Cancer Detection using Smoking Status and Standard Blood Test Analysis**
Margrethe Bang Henriksen, Vejle, Denmark
- 12:00 - 12:00 **159P - Optimization and Validation of a Circulating microRNA Biomarker Panel for Early Detection of Lung Cancer in a Japanese Population**
Joji Samejima, Kashiwa, Japan
- 12:00 - 12:00 **160P - Non-invasive analysis of VOCs in exhaled air can distinguish healthy controls from lung cancer patients and may improve the effectiveness of lung cancer screening.**
Sébastien Hulo, Lille, France
- 12:00 - 12:00 **162P - Targeting mitogenic addiction as a therapeutic vulnerability in neuroendocrine subtype of Small cell lung cancer**
Triparna Sen, New York, United States of America
- 12:00 - 12:00 **163P - Integrative analysis of small cell lung cancer patient-derived xenograft models reveals subtype-specific pathway alterations and therapeutic targets**
Triparna Sen, New York, United States of America

- 12:00 - 12:00 **164P - Immune cells distribution and spatial relationship within microenvironment as predictive biomarkers of benefit in extended stage Small Cell Lung Cancer patients receiving atezolizumab plus carboplatin and etoposide as first line treatment**
Giulia Pasello, Padova, Italy
- 12:00 - 12:00 **165P - SCLC subtypes are associated with distinct clinicopathological features and outcomes: a biomarker analysis from the CANTABRICO study.**
Pedro Simoes Da Rocha, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain
- 12:00 - 12:00 **166P - Investigating the correlation between circulating tumor cell (CTC) detection and immune checkpoint expression in the peripheral blood of patients with small cell-lung cancer (SCLC)**
Sofia Agelaki, Heraklion, Greece
- 12:00 - 12:00 **167P - Five-years incidence of SCLC and analysis of PM2.5 air pollution in the province of Brescia: preliminary results**
Salvatore Grisanti, Brescia, Italy
- 12:00 - 12:00 **168P - Demographics, Clinical Characteristics, Treatment (tx) Patterns and Clinical Outcomes for Patients (pts) with Limited-Stage SCLC (LS-SCLC)**
Anne Chiang, New Haven, United States of America
- 12:00 - 12:00 **169P - Phase I Dose Escalation Trial Combining Olaparib and Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer**
Andreas Rimner, New York, United States of America
- 12:00 - 12:00 **170P - Preliminary Results from LUMINANCE: a Phase 3b, Single-Arm Study of 1L Durvalumab (D) + Platinum-Etoposide (EP) for Patients with Extensive-Stage SCLC (ES-SCLC)**
Niels Reinmuth, Gauting, Germany
- 12:00 - 12:00 **171P - Comparison of etoposide/cisplatin and irinotecan/cisplatin for extensive-stage small-cell lung cancer in Koreans: A real-world retrospective observational study**
Eungbae Lee, Daegu, Korea, Republic of
- 12:00 - 12:00 **172P - A Chinese multicenter, real-world study of PD-L1 inhibitors in extensive stage small cell lung cancer**
Jianfeng Peng, Jinan, China
- 12:00 - 12:00 **173P - Extended-stage SCLC (ES-SCLC) patients treated with first-line Chemotherapy plus atezolizumab in Spain. Characteristics and outcomes.**
Pablo Mugarza, Zaragoza, Spain
- 12:00 - 12:00 **174TiP - PRIMALung (EORTC-1901): PRophylactic cerebral Irradiation or active brain MAgnetic resonance imaging surveillance in small-cell Lung cancer**

patients

Antonin Levy, Villejuif, France

- 12:00 - 12:00 **176P - Multi-omic analyses of lung cancer tumors show role of AKT and MYC as regulators of lung adenocarcinoma to squamous cell lung cancer transdifferentiation**
Triparna Sen, New York, United States of America
- 12:00 - 12:00 **177P - Dissecting the molecular landscape of resistance to ROS1 tyrosine kinase inhibitors with improved NSCLC pre-clinical models.**
Marc Terrones, Edegem, Belgium
- 12:00 - 12:00 **178P - Targeting XPO1-dependent nuclear export of HMGB1 in non-small cell lung cancer**
Maria Gonzalez Cao, Quirón-Dexeus University Institute, Barcelona, Spain
- 12:00 - 12:00 **179P - Integrative analysis revealed the signature of cancer stem cells and its immunosuppressive role in lung adenocarcinoma**
Guangyu Fan, Beijing, China
- 12:00 - 12:00 **181P - Comprehensive analysis on proteasome-related genes and theirs correlation with immunity and immunotherapy in squamous cell lung cancer**
Tongji Xie, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- 12:00 - 12:00 **182P - CD27-IgD- B cells might portray an exhausted B cell phenotype resulting in lack of response to checkpoint inhibitor treatment in NSCLC.**
Robert A Belderbos, Rotterdam, Netherlands
- 12:00 - 12:00 **183P - Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and gene marker CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single cell RNA sequencing**
Liling Huang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- 12:00 - 12:00 **184P - INHA acts as a Novel and Potential Biomarker in Lung Adenocarcinoma and Shapes the Immune-Suppressive Tumor Microenvironment**
Bo Cheng, Jinan, China
- 12:00 - 12:00 **185P - Influence of corticosteroids and antibiotics on the microbiota and the efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC)**
María Zapata García, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain
- 12:00 - 12:00 **186P - Elevated CXCL10:IL-8 ratio in bronchoalveolar lavage fluid of immune checkpoint inhibitor-related pneumonitis**

Pierre Van Mol, Leuven, Belgium

- 12:00 - 12:00 **187P - TISSUE B-CELL RECEPTOR REPERTOIRE AS BIOMARKER OF COMPLETE PATHOLOGICAL RESPONSE IN NSCLC PATIENTS TREATED WITH NEOADJUVANT CHEMOIMMUNOTHERAPY (NADIM TRIALS)**
Belén Sierra-Rodero, Majadahonda, Spain
- 12:00 - 12:00 **188P - SAKK 16/14: Immune profiling of pre-operative biopsies correlates with survival and immune activation in stage IIIA(N2) NSCLC after neoadjuvant immunotherapy**
Sacha Rothschild, Basel, Switzerland
- 12:00 - 12:00 **189P - The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC**
Giulia Mazzaschi, Parma, Italy
- 12:00 - 12:00 **190P - EORTC-SPECTA Arcagen project: results of the prospective rare thoracic tumors cohort**
Marco Tagliamento, Villejuif, France
- 12:00 - 12:00 **191P - ROS1 fusions in resected stage I-III adenocarcinoma (ADC), a Lungscape ETOP study**
Ernst-Jan Speel, Maastricht University Medical Center, Maastricht, Netherlands
- 12:00 - 12:00 **192P - ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations**
Pei Li Stephanie Saw, Singapore, Singapore
- 12:00 - 12:00 **193P - Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC**
Laura Pinto, Barcelona, Spain
- 12:00 - 12:00 **194P - Motion of lymph nodes and the effect on the dose coverage in proton therapy of lung cancer**
Djoya Hattu, Maastricht, Netherlands
- 12:00 - 12:00 **195P - Efficacy of Mobile health intervention on quality of life and symptom burden in lung cancer**
Karine Soulat, wellthytherapeutics, Mumbai, India
- 12:00 - 12:00 **196P - A causal Bayesian network structure for predicting dyspnea in lung cancer patients**
Cath Grivot, Maastricht, Netherlands
- 12:00 - 12:00 **197P - Combining stereotactic body radiation and low-dose radiation (EclipseRT) with PD-1 inhibitor in mice models and patients with bulky tumor**

Ren Luo, Chengdu, China

- 12:00 - 12:00 **198TiP - Immuno-PET in predicting immune checkpoint inhibitor response in non-small cell lung cancer**
Sónia Silva, Leiria, Portugal
- 12:00 - 12:00 **199P - Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET)and V-ATPase.**
Rafael Rosell, Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Spain
- 12:00 - 12:00 **200P - Dissecting mechanisms of resistance to new generation selective RET inhibitors in NSCLC**
Daniela Esposito, Naples, Italy
- 12:00 - 12:00 **201P - RNA-based plus DNA-based analysis of MET exon 14 skipping in a non-small cell lung cancer increases diagnostic performance**
Pedro Rafael De Marchi, Grupo Oncoclínicas Brasil, São Paulo, Brazil
- 12:00 - 12:00 **202P - Molecular Kaleidoscope of EGFR mutant NSCLC: Be as precise as possible**
Ullas Batra, New Delhi, India
- 12:00 - 12:00 **203P - MET gene copy number heterogeneity in non-small cell lung cancer patients resistant to EGFR-TKIs**
Qianming Bai, Shanghai, China
- 12:00 - 12:00 **204P - Dysbiosis of the gut microbiome impairs EGFR-tyrosine kinase inhibitors responses in H1975 xenografts Mice Models**
Yu-Mu Chen, Kaohsiung City, Taiwan
- 12:00 - 12:00 **205P - Modelling of NSCLC aPD1 responses in bronchoscopic biopsies on chip (bronchoBOCs)**
Maria Matthaiaiki Panagiotaki, BSRC Alexander Fleming, Vari-Voula-Vouliagmeni, Greece
- 12:00 - 12:00 **206P - Synchronous brain metastases and paired lung adenocarcinomas show similar methylation patterns**
Philipp Zens, Bern, Switzerland
- 12:00 - 12:00 **207P - Does age affect PD-L1 expression? Results of a single-center analysis of a large cohort of patients.**
Magdalena Knetki-Wroblewska, Warsaw, Poland
- 12:00 - 12:00 **208P - Lung Cancer: Precise Prediction**
Oleg Kshivets, Roshal, Russian Federation

- 12:00 - 12:00 **209P - Clinicopathological features and survival outcome of Keratinizing versus non-keratinizing squamous cell lung cancer**
Asmaa Ellaithy, Ismailia, Egypt
- 12:00 - 12:00 **210P - Expression of cancer stem cell markers SOX-2 and OCT-4 and their regulation by Nicotine in non-small cell lung carcinoma**
Jayanthi Pazhani, Chennai, India
- 12:00 - 12:00 **211P - The Impact of the Covid-19 Pandemic on Lung Cancer Stage Shift and the Delivery of Surgical Lung Cancer Care in the United States**
Alexandra Potter, Massachusetts General Hospital, Boston, United States of America
- 12:00 - 12:00 **212P - Impact of COVID-19 on the timeliness to care in a Rapid Access Lung Lesions Clinic in a large Australian cancer centre.**
Eve Malsem, Ballarat, Australia
- 12:00 - 12:00 **213P - Development of an explainable clinical decision support tool for advanced lung cancer patients**
Louise Berteloot, Roeselare, Belgium
- 12:00 - 12:00 **214P - Development of a nomogram to predict the progression free survival in lung cancer patients**
Hassan Tafenzi, Marrakech, Morocco
- 12:00 - 12:00 **215P - ASSESSMENT OF PATIENT AND CLINICIAN AWARENESS AND CLINICAL OUTCOMES OF CHANGES IN LIFESTYLE HABITS DURING LUNG CANCER TREATMENT;**
Ana Isabel Martin Quesada, Santa Cruz de Tenerife, Spain
- 12:00 - 12:00 **216P - Differences In Immune Checkpoint Inhibitor (ICI) Approvals made by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for Thoracic Malignancies**
Numair Rizwan, Hradec Kralove, Czech Republic
- 12:00 - 12:00 **217P - Robotic-assisted navigation system for preoperative percutaneous lung nodule localization: A pilot study**
Yuechun Lin, Guangzhou, China
- 12:00 - 12:00 **218P - Implications of the eighth edition of TNM staging system for thymoma, a single center retrospective study**
Iddo Vardi, Ramat Gan, Israel
- 12:00 - 12:00 **219P - Clinical outcomes for advanced thymoma patients receiving platinum-based chemotherapy as first-line treatment**
Yue Hao, Hangzhou, China

12:00 - 12:00	220P - Comparison of efficacy and safety of platinum-based chemotherapy as first-line therapy between B3 thymoma and thymic carcinoma <u>Yue Hao</u> , Hangzhou, China	
12:00 - 12:00	221P - Comparison of efficacy and safety of carboplatin combined with nab-paclitaxel or paclitaxel as first-line therapy for advanced thymic epithelial tumors <u>Yue Hao</u> , Hangzhou, China	
12:00 - 12:00	222P - Thoracic neuroendocrine tumors: Experience in a third level hospital in Mexico <u>Rodrigo Riera Sala</u> , Mexico City, Mexico	
12:00 - 12:00	223P - Surgery versus Bronchoscopic Cryotherapy for the treatment of Lung Carcinoid Tumors. An overview of five years experience. <u>Fatmir Caushi</u> , Tirana, Albania	
12:00 - 12:00	224P - Genetic Landscape, PD-L1 Expression, and CD8+ infiltration in Chinese Pulmonary Carcinoids <u>Ning Zhou</u> , Tianjin, China	
12:00 - 12:45	Type: Young Oncologists session Title: YO Mentorship session - Tips and trick when starting out in your career and establishing your research portfolio Moderation: Elene Mariamidze, Georgia; Kok Haw Jonathan Lim, United Kingdom	Foyer
12:00 - 12:00	Mentor <u>Laura Mezquita</u> , Barcelona, Spain	
12:00 - 12:00	Mentor <u>Antonio Passaro</u> , Milan, Italy	

12:45 - 14:15	Type: Industry Satellite Symposium Title: AstraZeneca - Screen, test & treat: New horizons in early stage NSCLC management Moderation: Niels Reinmuth, Germany	Auditorium 2
12:45 - 12:48	Welcome and introduction <u>Niels Reinmuth</u> , Gauting, Germany	
12:48 - 13:08	Striving for stage shift with early-stage NSCLC detection <u>Joachim Aerts</u> , Rotterdam, Netherlands	
13:08 - 13:23	Raising the bar in resectable EGFR mutated NSCLC <u>Isabelle Opitz</u> , University Hospital Zürich, Zurich, Switzerland	
13:23 - 13:38	Expanding the benefit of consolidation immunotherapy in unresectable NSCLC <u>Niels Reinmuth</u> , Gauting, Germany	
13:38 - 13:53	IO consolidation after CRT for unresectable NSCLC: From clinical trials to real-world practice <u>Fiona Mcdonald</u> , London, United Kingdom	
13:53 - 14:13	Discussion	
14:13 - 14:15	Summary and close <u>Niels Reinmuth</u> , Gauting, Germany	

12:45 - 14:15	Type: Special session Title: Lost in translation (Patient advocacy session) Moderation: Ewelina Szmytke, Switzerland; Shani Shilo, Israel	Auditorium 15
12:45 - 12:45	Health literacy in Europe <u>Luis Saboga-Nunes</u> , Freiburg, Germany	
12:45 - 13:05	What are health systems doing to improve health literacy? <u>Chloe Moore</u> , Dublin, Ireland	
13:05 - 13:25	The power of plain language and communication <u>Shani Shilo</u> , Rehovot, Israel	
13:25 - 13:45	Words hurt: Tackling lung cancer stigma <u>Ewelina Szmytke</u> , Bern, Switzerland	
13:45 - 13:55	Q&A and discussion	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Novocure GmbH - The evolving role of tumor treating fields therapy in thoracic oncology Moderation: Corey Langer, United States of America	Auditorium 4
12:45 - 12:50	Welcome and introduction <u>Corey Langer</u> , Philadelphia, United States of America	
12:50 - 13:05	The practice-changing experience with TTFields therapy in glioblastoma <u>Andreas Hottinger</u> , Lausanne, Switzerland	
13:05 - 13:20	The expanding experience with TTFields therapy in pleural mesothelioma <u>Federica Grosso</u> , Alessandria, Italy	
13:20 - 13:35	Is there a place for TTFields therapy in non-small cell lung cancer? <u>Corey Langer</u> , Philadelphia, United States of America	
13:35 - 14:05	Panel discussion: Evolving role of TTFields therapy in solid tumors <u>Andreas Hottinger</u> , Lausanne, Switzerland	
14:05 - 14:15	Concluding remarks and close <u>Corey Langer</u> , Philadelphia, United States of America	

14:30 - 15:00	Type: Keynote lecture Title: Air pollution and lung cancer Moderation: Martin Reck, Germany; Noemi Reguart Aransay, Spain	Auditorium 1
14:30 - 14:35	Introduction by the Chairs	
14:35 - 15:00	Air pollution and lung cancer <u>Charles Swanton</u> , London, United Kingdom	
15:10 - 16:40	Type: Special session Title: Language is more than words (Patient advocacy session) Moderation: Diego Villalon, Spain; Merel Hennink, Netherlands	Auditorium 15
15:10 - 15:30	Informed consent: What does it mean? <u>Diego Villalon</u> , Barcelona, Spain	
15:30 - 15:50	Is shared decision making a reality in the care pathway? <u>Merel Hennink</u> , Utrecht, Netherlands	
15:50 - 16:10	Prognostic communication <u>Nicoletta Mitrea</u> , Bucharest, Romania	
16:10 - 16:30	Language and its role in health equity <u>Torsten Blum</u> , Berlin, Germany	
16:30 - 16:40	Q&A and discussion	

15:10 - 16:40	Type: Educational session Title: Mediastinal tumours Moderation: Enrico Ruffini, Italy; Malgorzata Szolkowska, Poland	Auditorium 4
15:10 - 15:30	9th edition of the TNM stage classification of thymic tumors: Final recommendations to UICC/AJCC <u>Enrico Ruffini</u> , Torino, Italy	
15:30 - 15:50	What is new in the 2021 WHO classification of thymic epithelial, germ cell and mesenchymal tumors <u>Malgorzata Szolkowska</u> , Warsaw, Poland	
15:50 - 16:10	Mediastinal germ cell tumors: Update on diagnosis and multidisciplinary management <u>Kenneth Kesler</u> , Indianapolis, United States of America	
16:10 - 16:30	The importance of a collaborative global effort among National and International Societies <u>Vincent Fang</u> , Shanghai, China	
16:30 - 16:40	Q&A	

15:10 - 16:40	Type: Educational session Title: EGFR mutations and ALK rearrangements: Where are we now and where do we need to go to optimize treatment paradigms for our patients? Moderation: Heather Wakelee, United States of America; Mariana Brandão, Belgium	Auditorium 1
15:10 - 15:30	Local control strategies for management of oligoprogressive disease <u>Antonin Levy</u> , Villejuif, France	
15:30 - 15:50	Strategies to overcome resistance to EGFR and ALK TKIs <u>Mariana Brandão</u> , Brussels, Belgium	
15:50 - 16:10	Moving EGFR and ALK TKIs into earlier stage disease <u>Margarita Majem Tarruella</u> , Hospital de la Santa Creu i Sant Pau, Barcelona, Spain	
16:10 - 16:30	Beyond ex19del and L858R: Update on EGFRex20 insertions and other uncommon EGFR mutations <u>Xiuning Le</u> , Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States of America	
16:30 - 16:40	Q&A	
15:10 - 16:40	Type: Special Symposium Title: Genotyping in NSCLC: Monitoring, germline alterations, minimal residual disease Moderation: Anne-Marie Baird, Ireland; Rafal Dziadziuszko, Poland	Auditorium 2
15:10 - 15:30	The real-world impact of genotyping in NSCLC <u>Anne-Marie Baird</u> , Dublin, Ireland	
15:30 - 15:50	Utility of genotyping in monitoring disease evolution and treatment response <u>Rafal Dziadziuszko</u> , Medical University of Gdansk, Gdansk, Poland	
15:50 - 16:10	Is it in the germline: NSCLC as a hereditary disease <u>Patrick Benusiglio</u> , Paris, France	
16:10 - 16:30	Value of genotyping in the assessment of minimum residual disease <u>Luis Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
16:30 - 16:40	Q&A	
16:40 - 17:00	Type: Coffee break Title: Coffee break	Exhibition and Poster area

17:00 - 18:30	Type: Educational session Title: Toxicity management of immunotherapy with a focus on patients with contraindications Moderation: Christian Rolfo, United States of America; Milica Kontic Jovanovic, Serbia	Auditorium 2
----------------------	--	---------------------

17:00 - 17:20	Relative and definitive contra-indication for ICI <u>Niels Reinmuth</u> , Gauting, Germany	
17:20 - 17:40	Immune checkpoint inhibitors in transplanted patients <u>Enriqueta Felip</u> , Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain	
17:40 - 18:00	Immune checkpoint inhibitors in patients with pulmonary fibrosis <u>Milica Kontic Jovanovic</u> , Belgrade, Serbia	
18:00 - 18:20	ICI induced Myasthenia Gravis <u>Waleed Kian</u> , Beer Sheva, Israel	
18:20 - 18:30	Q&A	

17:00 - 18:30	Type: Multidisciplinary Tumour Board Title: NSCLC: Brain metastases Moderation: Antonin Levy, France; Samreen Ahmed, United Kingdom	Auditorium 1
----------------------	---	---------------------

17:00 - 17:10	Case presentation: Brain metastases in non-oncogene addicted NSCLC <u>Sara Ramella</u> , Rome, Italy	
17:10 - 17:30	Surgical perspective: Optimal patient selection, approach & timing <u>Timothy Jones</u> , London, United Kingdom	
17:30 - 17:50	Radiotherapy perspective: Optimal patient selection, approach & timing <u>Nicolaus Andratschke</u> , Zurich, Switzerland	
17:50 - 18:10	Medical oncology perspective: When is SACT alone enough? <u>Samreen Ahmed</u> , Leicester, United Kingdom	
18:10 - 18:30	Q&A	

17:00 - 18:30	Type: Educational session Title: Challenges and shifting paradigms in clinical trial designs Moderation: Klaus Pantel, Germany; Urania Dafni, Greece	Auditorium 4
17:00 - 17:20	The value of "early" endpoints (MPR, pCR) in neoadjuvant trials <u>Mariano Provencio Pulla</u> , Majadahonda, Spain	
17:20 - 17:40	Can we use liquid biopsies to optimize patient selection for clinical trials? <u>Klaus Pantel</u> , Hamburg, Germany	
17:40 - 18:00	Challenges in early phase immunotherapy clinical trial design <u>Urania Dafni</u> , National and Kapodistrian University of Athens, Athens, Greece	
18:00 - 18:20	How to rationally design immunotherapy combination trials? <u>Paolo Bironzo</u> , Orbassano, Italy	
18:20 - 18:30	Q&A	

17:00 - 18:30	Type: Young Oncologists session Title: YO Clinical Case discussion Moderation: Elene Mariamidze, Georgia; Kok Haw Jonathan Lim, United Kingdom	Auditorium 15
17:00 - 17:05	Welcome and introduction	
17:05 - 17:15	Clinical case 1 - Targeted therapy in ROS1-positive advanced squamous-NSCLC <u>Ana Valenzuela</u> , Ciudad de Mexico, Mexico	
17:15 - 17:25	Mentor - Panel discussion <u>Martin Reck</u> , Airway Research Center North, German Center for Lung Research, Lung Clinic, Grosshansdorf, Germany	
17:25 - 17:35	Clinical case 2 - Immunotherapy in pleural mesothelioma <u>Sylwia Tabor</u> , Warsaw, Poland	
17:35 - 17:45	Mentor - Panel discussion <u>Alessandra Curioni</u> , University of Fribourg, Fribourg, Switzerland	
17:45 - 17:55	Clinical case 3 - Molecular profiling in extensive-stage SCLC <u>Lodovica Zullo</u> , Genova, Italy	
17:55 - 18:05	Mentor - Panel discussion <u>Martin Reck</u> , Airway Research Center North, German Center for Lung Research, Lung Clinic, Grosshansdorf, Germany	
18:05 - 18:30	Q&A and discussion	

18:45 - 20:15	Type: Industry Satellite Symposium Title: GSK - Latest scientific advances and investigational approaches with IO in NSCLC Moderation: David Planchard, France	Auditorium 4
18:45 - 19:05	The latest in checkpoint inhibition <u>Natasha Leighl</u> , Princess Margaret Cancer Centre, Toronto, Canada	
19:05 - 19:25	Advances in novel IO combinations <u>Niels Reinmuth</u> , Gauting, Germany	
19:25 - 19:45	Ongoing IO trials & potential implications <u>David Planchard</u> , Villejuif, France	
19:45 - 20:05	Panel Discussion and Q&A	
18:45 - 20:15	Type: Industry Satellite Symposium Title: AstraZeneca - Overcoming challenges and navigating treatment decisions in metastatic NSCLC Moderation: Frank Griesinger, Germany	Auditorium 2
18:45 - 18:48	Welcome and introduction <u>Frank Griesinger</u> , Oldenburg, Germany	
18:48 - 19:08	Unmet needs in advanced NSCLC management <u>Tanya Ahmad</u> , London, United Kingdom	
19:08 - 19:28	Management of brain metastases in NSCLC: Evolving roles for radiation and systemic treatments <u>Dirk De Ruysscher</u> , Maastrro Clinic, Maastricht, Netherlands	
19:28 - 19:48	Metastatic NSCLC: A personalised treatment approach <u>Frank Griesinger</u> , Oldenburg, Germany	
19:48 - 20:13	Panel discussion and Q&As	
20:13 - 20:15	Summary and close <u>Frank Griesinger</u> , Oldenburg, Germany	

01.04.2023

08:30 - 10:00	Type: Educational session Title: Oligometastasis of lung cancer: Crosspoint of multidisciplinary treatment Moderation: Helena Linardou, Greece; Nan Wu, China	Auditorium 4
----------------------	---	---------------------

08:30 - 08:50	Oligometastases of lung cancer: Guidelines and beyond <u>Helena Linardou</u> , Metropolitan Hospital, Athens, Greece	
08:50 - 09:10	Liquid biopsy: A useful tool for oligometastases? <u>Evi Lianidou</u> , Athens, Greece	
09:10 - 09:30	Role of radiation in oligometastases of lung cancer: Consensus and controversy <u>Niccolò Giaj-Levra</u> , Negrar di Valpolicella, Italy	
09:30 - 09:50	Surgical perspectives for oligometastases of lung cancer: Where is the ceiling? <u>Nan Wu</u> , Beijing, China	
09:50 - 10:00	Q&A	

08:30 - 10:00	Type: Special Symposium Title: CART-T cells in lung cancer Moderation: John Haanen, Netherlands; Solange Peters, Switzerland	Auditorium 2
----------------------	--	---------------------

08:30 - 08:50	Principles of T-cell therapies and CAR-T cells in solid tumors <u>John Haanen</u> , Amsterdam, Netherlands	
08:50 - 09:10	Evidence of efficacy and TILs data in NSCLC <u>Ben Creelan</u> , Tampa, United States of America	
09:10 - 09:30	Opportunities and data for CAR-T cells in solid tumors and NSCLC <u>Prasad Adusumilli</u> , New York, United States of America	
09:30 - 09:50	Future prospect, challenges and trials of cellular therapies in NSCLC <u>Martin Forster</u> , London, United Kingdom	
09:50 - 10:00	Q&A	

10:00 - 10:15	Type: Coffee break Title: Coffee break	Exhibition and Poster area
----------------------	---	-----------------------------------

10:15 - 11:45	Type: Educational session Title: Stage IIIA patients: Surgical and non-surgical treatment in the context of IO Moderation: Alessandro Brunelli, United Kingdom; Sara Ramella, Italy	Auditorium 4
10:15 - 10:35	Surgery after neoadjuvant IO in stage III NSCLC <u>Alessandro Brunelli</u> , Leeds, United Kingdom	
10:35 - 10:55	Can radiotherapy replace surgery as the local treatment of stage III NSCLC in the era of IO <u>Sara Ramella</u> , Rome, Italy	
10:55 - 11:15	Redefining surgical needs in the era of neoadjuvant IO: Resectability and mediastinal staging techniques <u>Jean Yannis Perentes</u> , Lausanne, Switzerland	
11:15 - 11:35	Local and distant relapse after curative treatment in the context of neoadjuvant IO: What's next? <u>Idris Bahce</u> , Amsterdam, Netherlands	
11:35 - 11:45	Q&A	
10:15 - 11:45	Type: Educational session Title: First-Line immunotherapy in NSCLC: How to select and where to go? Moderation: Solange Peters, Switzerland; Martin Reck, Germany	Auditorium 2
10:15 - 10:35	Exploring the lung cancer evolution and immune escape <u>Nicholas Mcgranahan</u> , London, United Kingdom	
10:35 - 10:55	Monotherapy with checkpoint inhibitors <u>Martin Reck</u> , Airway Research Center North, German Center for Lung Research, Lung Clinic, Grosshansdorf, Germany	
10:55 - 11:15	Opportunities and limitations <u>Marina Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, United States of America	
11:15 - 11:35	Immunotherapy combinations: How to select? <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
11:35 - 11:45	Q&A	

